A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

Green Cross Corporation

Status and phase: Completed; Phase 1

Conditions: Chronic Hepatitis B

Treatments: Biological: GC1102

Study type: Interventional

Funder types: Industry

Identifiers

NCT02569372

GC1102B_P1

Details and patient eligibility

About

This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B Patients.

Full description

GC1102 is a new recombinant hepatitis B human immunoglobulin. This study is composed with 2 Parts, Part A for SAD and Part B for MAD and total 4 dosing program which is escalated after confirming safety. Maximum 48 subjects will be participated in the study.

Enrollment: 53 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic hepatitis B or those who diagnosed with chronic hepatitis B carrier who given written informed consent.
• Patients aged ≥19 and ≤ 65 years
• If Naïve for the Nucleos(t)ide analogs therapy, HBeAg (-), HBsAg 1,000 IU/mL or less and HBV DNA 2,000IU/mL or less Or If currently receiving Nucleos(t)ide analogs therapy, HBeAg (±), HBsAg 1,000 IU/mL or less and HBV DNA (-: limit of detection of 60 IU/mL or less).

Exclusion criteria

• Patients who currently involved or has participated in any other clinical trial within 30 days.
• Patients co-infected with HAV, HCV or HIV
• Patients with history of malignant tumor within 5 years except basal cell carcinoma of skin, cervical intraepithelial neoplasia.
• Patients who have active infection except chronic hepatitis infection.
• Patients with liver disease who had complications such as gastroesophageal variceal, ascites and hepatic encephalopathy.
• Having eGFR 59 mL/min/1.73m2 or less with MDRD Evaluation phase (moderate reduction in GFR or more )
• Having blood or protein 1+ or more by the urine analysis with microscopic examination.
• Patients who have a clinically significant kidney disease including glomerulonephritis, anuria, acute renal failure, dialysis and renal transplantation.
• Patients with Vasculitis.
• Having leukocytes <3.0 x109/L
• Having Absolute Neutrophil Count<1.5x109/L
• Having platelet <750,000/mm3 during screening
• Having hemoglobin <10g/dL
• Having positive sign of serum cryoglobulin level.
• Having serum anti-nuclear antibody (ANA) 1:160 or more
• Patients who showed positive sign of serum perinuclear anti-Neutrophil Cytoplasmic Antibodies (p-ANCA).
• Patients who showed positive sign of serum cytoplasmic anti-Neutrophil Cytoplasmic Antibodies (c-ANCA).
• Patients who had history or be suspected of immune disease
• Patients who had experienced cardiovascular attack, myocardiac infarction, heart failure, PTCA or coronary artery bypass, angina, arrhythmia, any other clinically meaningful valvular heart disease, cerebral infarction or cerebral hemorrhage within 6 months.
• Patients who had history of anaphylaxis against the main component or subcomponent of study drug.
• Patients who had been administered live vaccine parentally (measles vaccine, parotitis vaccine, rubella vaccine, cholera combined vaccine, varicella vaccine) within 3 months prior to the dosing of study drug.
• Patients who had been received an immunosuppressant, immunity-modifying drug including interferon agents, cytotoxic chemotherapy that can affect their immune system, or radiation therapy within 3 months prior to the dosing of study drug
• Patients who had been treated with any other immunoglobulin within 3 months prior to the dosing of study drug
• Patients who had been treated with systemic steroid Therapy(more than 20 mg/day of prednisolone or its equivalence administered every day for more than 14 days, or more than 700 mg of a cumulative dose during the same period of time) within 3 months prior to the dosing of study drug (topical administration such as topical ointments, eye drops, inhalants or intranasal use, intra-articular injection, or tendon injection is acceptable; alternative-day treatment is acceptable even though administered for more than 14 days)
• Women who showed positive sign of pregnancy test before administered study drug.
• Those who do not agree to use appropriate contraceptive methods (condom, diaphoretic, an intrauterine device, oral contraceptive hormones, or a vasectomy of male sex partner) during the clinical trials.
• Those who had experienced bleeding more 400ml or a blood donation within 8 weeks prior to the dosing of study drug.
• Those who had been abused alcohol or any other drug within 6 months.
• Those who are judged disqualified to join clinical trials by investigator for other clinically significant medical or psychiatric condition.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

53 participants in 8 patient groups

GC1102 80,000 IU(Single does)

Experimental group

Description:

GC1102 80,000 IU(Single does) I.V.

Treatment:

Biological: GC1102

GC1102 120,000 IU(Single does)

Experimental group

Description:

GC1102 120,000 IU(Single does) I.V.

Treatment:

Biological: GC1102

GC1102 180,000 IU(Single does)

Experimental group

Description:

GC1102 180,000 IU(Single does) I.V.

Treatment:

Biological: GC1102

GC1102 240,000 IU(Single does)

Experimental group

Description:

GC1102 240,000 IU(Single does) I.V.

Treatment:

Biological: GC1102

GC1102 80,000 IU(Multiple does)

Experimental group

Description:

GC1102 80,000 IU(Multiple does) I.V.

Treatment:

Biological: GC1102

GC1102 120,000 IU(Multiple does)

Experimental group

Description:

GC1102 120,000 IU(Multiple does) I.V.

Treatment:

Biological: GC1102

GC1102 180,000 IU(Multiple does)

Experimental group

Description:

GC1102 180,000 IU(Multiple does) I.V.

Treatment:

Biological: GC1102

GC1102 240,000 IU(Multiple does)

Experimental group

Description:

GC1102 240,000 IU(Multiple does) I.V.

Treatment:

Biological: GC1102